Last reviewed · How we verify
Infection due to Escherichia coli
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Garamycin · Merck & Co.
- Cefaprin · Bristol-Myers Squibb
- Amoxycillin · King George's Medical University
- Tobi · Novartis
- Unasyn · Bristol-Myers Squibb
- Unasyn · Pfizer
- Coly-Mycin M · Ph Health
- Pipracil
Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death. - Amoxil · Generic (originally Beecham/GSK)
Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins. - Ciprofloxacine · Poitiers University Hospital
- Vantobra · Pfizer
- Gentamicin · Merck & Co.
- colimycin · Poitiers University Hospital
- Cefadole
Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. - Nebcin · University Hospital, Lille
- Coly-Mycin S · Par Sterile Products
- Ceftriaxon · Centre Hospitalier Universitaire Vaudois
- Azactam · Bristol-Myers Squibb
Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent. - Arikayce Kit · Bristol-Myers Squibb
Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria. - Fortaz · Pai Holdings Pharm
Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death. - Mefoxin In Sodium Chloride 0.9% In Plastic Container
- Teflaro · AbbVie
Teflaro works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. - Cefotan
- TICARCILLIN
- Ticarcillin
- Zinacef · GSK
Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. - Augmentin 250 · Dr Reddys Labs Inc
- Fortaz · Pai Holdings Pharm
Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance. - Noroxin
- Floxin
- Epocelin
- Cipro · Bayer AG
- Rocephin · Generic (originally Roche)
- Ceftazidim · Tel-Aviv Sourasky Medical Center
- Ofloxacine · Assistance Publique - Hôpitaux de Paris
- Amoxicilli · Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Infection due to Escherichia coli patent landscape — cliff calendar, originator estates, attackable patents
- Infection due to Escherichia coli treatment landscape brief
- Infection due to Escherichia coli treatment updates RSS
Frequently asked questions about Infection due to Escherichia coli
What drugs treat Infection due to Escherichia coli?
Tracked treatments include Ramycin, Garamycin, Cefaprin, Amoxycillin, Tobi, Unasyn, Coly-Mycin M, Pipracil.
What is the treatment for Infection due to Escherichia coli?
Standard treatment for Infection due to Escherichia coli includes Ramycin, Garamycin, Cefaprin, Amoxycillin, Tobi. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Infection due to Escherichia coli patent cliff · Infection due to Escherichia coli CI report
- Treatment: Ramycin
- Treatment: Garamycin · Merck & Co.
- Treatment: Cefaprin · Bristol-Myers Squibb
- Treatment: Amoxycillin · King George's Medical University
- Treatment: Tobi · Novartis
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing